STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-04-19
Here’s whether Exelixis Inc (EXEL) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.74% over 10 days); strong 1-year return of +24.2%. Currently 9.5% off its 52-week high. Score: +5/7.
EXEL is in a confirmed uptrend, trading above both its 50-day ($43.02) and 200-day ($41.66) moving averages. An RSI of 68.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +24.2% compares to +35.1% for SPY (trailed the market by 10.9%).
$10,000 invested 1 year ago→ $12,418 today
vs. S&P 500 (SPY) — same period trailed market by 10.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($41.66)
✓Above 50-day MA ($43.02)
✓RSI(14) neutral zone (30–70) — currently 68.4
✓Positive return (+24.2%)
✓Within 10% of period high (−9.5%)
Period Range $44.89
$33.76$49.62
RSI (14) 68.4
0 · OversoldOverbought · 100
Key Metrics
Price$44.89
Period Return+24.2%
Period High$49.62
Period Low$33.76
Drawdown−9.5%
MA-50$43.02
MA-200$41.66
RSI (14)68.4
Avg Volume (30d)2.5M
vs. SPYtrailed by 10.9%
Return Rank#529 of 996
Trend Signals
Price is above the 200-day moving average ($41.66)